Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors

Infection and Immunity

Volumn 67, Issue 6, 1999, Pages 2957-2963

  Cirino, Nick M ^a   Sblattero, Daniele ^b   Allen, David ^a   Peterson, Scott R ^a   Marks, James D ^c   Jackson, Paul J ^a   Bradbury, Andrew ^b   Lehnert, Bruce E ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b SISSA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; CELL SURFACE RECEPTOR; GREEN FLUORESCENT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTHRAX; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BACILLUS ANTHRACIS; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHINESE HAMSTER; CYTOMETRY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; TOXICITY;

EID: 0033055641     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.6.2957-2963.1999     Document Type: Article

References (54)

1. Benson, E. L., P. D. Huynh, A. Finkelstein, and R. J. Collier. 1998. Identification of residues lining the anthrax protective antigen channel. Biochemistry 37:3941-3948.
2. Blaustein, R. O., T. M. Koehler, R. J. Collier, and A. Finkelstein. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid-bilayers. Proc. Natl. Acad. Sci. USA 86:2209-2213.
3. Boonham, N., and I. Barker. 1998. Strain-specific recombinant antibodies to potato-virus-Y potyvirus. J. Virol. Methods 74:193-199.
4. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645.
5. Bradbury, A., L. Persic, T. Werge, and A. Cattaneo. 1993. Use of living columns to select specific phage antibodies. Bio/Technology 11:1565-1569.
6. Dorsam, H., P. Rohrbach, T. Kurschner, S. Kipriyanov, S. Renner, M. Braunagel, M. Welschof, and M. Little. 1997. Antibodies to steroids from a small human naive IgM library. FEBS Lett. 414:7-13.
7. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vandewoude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
8. Escuyer, V., and R. J. Collier. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386.
9. Farchaus, J. W., W. J. Ribot, S. Jendrek, and S. F. Little. 1998. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl. Environ. Microbiol. 64: 982-991.
10. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
11. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82-87.
12. Gordon, V. M., A. Rehemtulla, and S. H. Leppla. 1997. A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen. Infect. Immun. 65:3370-3375.
13. Griffiths, A. D., S. C. Williams, O. Hartley, I. M. Tomlinson, P. Waterhouse, W. L. Crosby, R. E. Kontermann, P. T. Jones, N. M. Low, T. J. Allison, T. D. Prospero, H. R. Hoogenboom, A. Nissim, J. P. L. Cox, J. L. Harrison, M. Zaccolo, E. Gherardi, and G. Winter. 1994. Isolation of high-affinity human-antibodies directly from large synthetic repertoires. EMBO J. 13:3245-3260.
14. Hammond, S. E., and P. C. Hanna. 1998. Lethal factor active-site mutations affect catalytic activity in vitro. Infect. Immun. 66:2374-2378.
15. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90:10198-10201.
16. Henderikx, P., M. Kandilogianaki, C. Petrarca, S. Vonmensdorffpouilly, J. H. M. Hilgers, E. Krambovitis, J. W. Arends, and H. R. Hoogenboom. 1998. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 58:4324-4332.
17. Klimpel, K. R., S. S. Molloy, G. Thomas, and S. H. Leppla. 1992. Anthrax toxin protective antigen is activated by a cell-surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 89:10277-10281.
18. Koehler, T. M., and R. J. Collier. 1991. Anthrax toxin protective antigen: low-pH-induced hydrophobicity and channel formation in liposomes. Mol. Microbiol. 5:1501-1506.
19. Krebs, B., H. Griffin, G. Winter, and S. Rosejohn. 1998. Recombinant human single-chain Fv antibodies recognizing human interleukin-6: specific targeting of cytokine-secreting cells. J. Biol. Chem. 273:2858-2865.
20. Leppla, S. H. 1991. The anthrax toxin complex, p. 277-302. In J. H. F. J. E. Alouf (ed.), Sourcebook of bacterial protein toxins. Academic Press, London, England.
21. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate-cyclase that increases cyclic-AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3156.
22. Leppla, S. H. 1988. Production and purification of anthrax toxin. Methods Enzymol. 165:103-116.
23. Leppla, S. H., A. M. Friedlander, and E. M. Cora. 1988. Proteolytic activation of anthrax toxin bound to cellular receptors, p. 111-112. In F. Fehrenbach, J. E. Alouf, P. Falmagne, W. Goebel, J. Jelaszewics, D. Jurgens, and R. Rappuoli (ed.), Bacterial protein toxins. Gustav Fischer Verlag, Stuttgart, Germany.
24. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
25. Little, S. F., S. H. Leppla, J. W. Burnett, and A. M. Friedlander. 1994. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal-antibodies. Biochem. Biophys. Res. Commun. 199:676-682.
26. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor-binding and cell-receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715.
27. Malmborg, A. C., M. Duenas, M. Ohlin, E. Soderlind, and C. Borrehaeck. 1996. Selection of binders from phage displayed antibody libraries using the BIAcore biosensor. J. Immunol. Methods 198:51-57.
28. Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter. 1991. Bypassing immunization: human-antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
29. McCafferty, J. 1998. Antibodies from phage display as genomics tools and therapeutic agents. IBC Antibody Engineering Conference, Coronado, Calif.
30. Milne, J. C., D. Furlong, P. C. Hanna, J. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms ring-shaped oligomers during intoxication of mammalian cells. FASEB J. 8:A1464.
31. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
32. Neri, D., B. Carnemolla, A. Nissim, A. Leprini, G. Querze, E. Balza, A. Pini, L. Tarli, C. Halin, P. Neri, L. Zardi, and G. Winter. 1997. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15:1271-1275.
33. Novak, J. M., M. P. Stein, S. F. Little, S. H. Leppla, and A. M. Friedlander. 1992. Functional characterization of protease-treated Bacillus anthracis protective antigen. J. Biol. Chem. 267:17186-17193.
34. Osbourn, J. K., A. Field, J. Wilton, E. Derbyshire, J. C. Earnshaw, P. T. Jones, D. Allen, and J. McCafferty. 1996. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 2:181-196.
35. Perelson, A. S., and G. F. Oster. 1979. Theoretical studies of clonal selection: minimal antibody repertoire size and reliability of self-non-self discrimination. J. Theor. Biol. 81:645-670.
36. Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal-structure of the anthrax toxin protective antigen. Nature 385: 833-838.
37. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477.
38. Puziss, M., L. C. Manning, L. W. Lynch, E. Barclay, I. Abelow, and G. G. Wright. 1963. Large-scale production of protective antigen of Bacillus anthracis anaerobic cultures. Appl. Microbiol. 11:330-334.
39. Quinn, C. P., C. C. Shone, P. C. B. Turnbull, and J. Melling. 1988. Purification of anthrax-toxin components by high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography. Biochem. J. 252: 753-758.
40. Robertson, D., T. Bragg, S. Simpson, R. Kaspar, W. Xie, and M. Tippetts. 1990. Mapping and characterization of the Bacillus anthracis plasmids pXO1 and pXO2. Salisbury Med. Bull. 68(Special Suppl.):55-58.
41. Schier, R., J. Bye, G. Apell, A. McCall, G. P. Adams, M. Malmqvist, L. M. Weiner, and J. D. Marks. 1996. Isolation of high-affinity monomeric human anti-c-erbB-2 single-chain Fv using affinity-driven selection. J. Mol. Biol. 255:28-43.
42. Schier, R., J. D. Marks, E. J. Wolf, G. Apell, C. Wong, J. E. McCartney, M. A. Bookman, J. S. Huston, L. L. Houston, L. M. Weiner, and G. P. Adams. 1995. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73-81.
43. Sheets, M. D., P. Amersdorfer, K. Finnern, P. Sargent, E. Lindqvist, R. Schier, G. Hemingsen, C. Wong, J. C. Gerhart, and J. D. Marks. 1998. Efficient construction of a large non-immune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95:6157-6162.
44. Singh, Y., V. K. Chaudhary, and S. H. Leppla. 1989. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J. Biol. Chem. 264:19103-19107.
45. Singh, Y., B. E. Ivins, and S. H. Leppla. 1998. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect. Immun. 64:3447-3448.
46. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor-binding and anthrax toxin activity. J. Biol. Chem. 264:15493-15497.
47. Takekoshi, M., F. Maeda, H. Tachibana, H. Inoko, S. Kato, I. Takakura, T. Kenjyo, S. Hiraga, Y. Ogawa, T. Horiki, and S. Ihara. 1998. Human monoclonal anti-HCMV neutralizing antibody from phage display libraries. J. Viral. Methods 74:89-98.
48. Tordsson, J., L. Abrahmsen, T. Kalland, C. Ljung, C. Ingvar, and T. Brodin. 1997. Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue-sections. J. Immunol. Methods 210:11-23.
49. van Ewijk, W., J. de Kruif, W. T. V. Germeraad, P. Berendes, C. Ropke, P. P. Platenburg, and T. Logtenberg. 1997. Subtractive isolation of phage displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments. Proc. Natl. Acad. Sci. USA 94:3903-3908.
50. Vaughan, T. J., A. J. Williams, K. Pritchard, J. K. Osbourn, A. R. Pope, J. C. Earnshaw, J. McCafferty, R. A. Hodils, J. Wilton, and K. S. Johnson. 1996. Human antibodies with subnanomolar affinities isolated from a large nonimmunized phage display library. Nat. Biotechnol. 14:309-314.
51. Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAP-K-Ks and induces tyrosine/threonine phosphorylation of MAP-Ks in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711.
52. Wang, X. M., R. Wattiez, M. Mock, P. Falmagne, J. M. Ruysschaert, and V. Cabiaux. 1997. Structure and interaction of PA63 and EF (edema toxin) of Bacillus anthracis with lipid-membrane. Biochemistry 36:14906-14913.
53. Winter, G., A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12: 433-455.
54. Witte, L., D. J. Hicklin, Z. P. Zhu, B. Pytowski, H. Kotanides, P. Rockwell, and P. Bohlen. 1998. Monoclonal-antibodies targeting the vEGF receptor-2 (Flkl/Kdr) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17:155-161.